FOXO

FOXO is not an operating story you can underwrite — it's a distressed shell being reassembled through acquisitions. The auditor has issued an explicit going-concern paragraph, and management states plainly it 'does not have adequate cash resources to fund operations through December 2026.' The balance sheet confirms it: just $207K of cash against $28.7M of current liabilities (current ratio ~0.11, current assets $3.11M), operating cash flow of -$3.87M, and an accumulated deficit of -$225M. Stockholders' equity is a thin $11.1M with liabilities/equity at 3.01x. This is a company living hand-to-mouth, and the one financing lifeline (the Strata Purchase Agreement) is inaccessible because the low price and thin volume fail its draw conditions.

The headline 'revenue +304%' to $16.4M is entirely inorganic — it comes from bolting on a 30-bed behavioral-health facility (Myrtle), a critical-access hospital (BSF), and a biospecimen sourcing business (Vector), all acquired in 2024-2025. There is no profitable core: gross margin is ~0.1%, operating margin -63.1%, net margin -75.9%, ROE -111.5%. The original epigenetics 'Labs' thesis has effectively been abandoned — R&D is a trivial $182K, down 41.6%. So you're paying for a roll-up of tiny, low-margin healthcare assets with no demonstrated ability to generate cash.